Suchergebnisse - "Schmid, Peter"

PubPharm (140)

1

Impact of pembrolizumab versus chemotherapy on health-related quality of life in patients with metastatic triple-negative breast cancer : results from the phase 3 randomised KEYNOTE-119 study

enthalten in: European journal of cancer (Oxford, England : 1990) | 2023

von Schmid, P. | Lipatov, O. | Im, S. | +18

2

Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02) : a randomised, open-label, multicentre, phase 3 trial

enthalten in: Lancet (London, England) | 2023

von Rugo, H. | Bardia, A. | Marmé, F. | +15

CommentIn: Nat Rev Clin Oncol. 2023 Nov;20(11):734. - PMID 37684406

3

XENERA-1 : a randomised double-blind Phase II trial of xentuzumab in combination with everolimus and exemestane versus everolimus and exemestane in patients with hormone receptor-positive/HER2-negative metastatic breast cancer and non-visceral disease

enthalten in: Breast cancer research : BCR | 2023

von Schmid, P. | Cortes, J. | Joaquim, A. | +13

4

Association Between Biomarkers and Clinical Outcomes of Pembrolizumab Monotherapy in Patients With Metastatic Triple-Negative Breast Cancer : KEYNOTE-086 Exploratory Analysis

enthalten in: JCO precision oncology | 2023

von Loi, S. | Salgado, R. | Schmid, P. | +20

5

Palbociclib with Fulvestrant or Letrozole in Endocrine-Sensitive Patients with HR-Positive/HER2-Negative Advanced Breast Cancer : A Detailed Safety Analysis of the Randomized PARSIFAL Trial

enthalten in: The oncologist | 2023

von Di Cosimo, S. | Pérez-García, J. | Bellet, M. | +20

6

NEPTUNE : Phase 3 Study of First-Line Durvalumab Plus Tremelimumab in Patients With Metastatic NSCLC

enthalten in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer | 2023

von de Castro, G. | Rizvi, N. | Schmid, P. | +20

CommentIn: J Thorac Oncol. 2023 Jan;18(1):29-30. - PMID 36543434

7

Evaluation of triple negative breast cancer with heterogeneous immune infiltration

enthalten in: Frontiers in immunology | 2023

von Quintana, �. | Arenas, E. | Bernadó, C. | +10

8

Sacituzumab Govitecan in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2022

von Rugo, H. | Bardia, A. | Marmé, F. | +13

CommentIn: J Clin Oncol. 2023 Feb 1;41(4):732-735. - PMID 36446052

9

A local human Vδ1 T cell population is associated with survival in nonsmall-cell lung cancer

enthalten in: Nature cancer | 2022

von Wu, Y. | Biswas, D. | Usaite, I. | +118

CommentIn: Nat Cancer. 2022 Jun;3(6):657-658. - PMID 35764741

10

Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer

enthalten in: The New England journal of medicine | 2022

von Schmid, P. | Cortes, J. | Dent, R. | +128

CommentIn: Nat Rev Clin Oncol. 2022 Apr;19(4):220. - PMID 35217781

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[14]